SCHEMBL24130446

SCHEMBL24130446

COc1c(N2CCN(C(=O)OC(C)(C)C)CC2)cccc1[N+](=O)[O-]

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.57
ALDH1A1 P00352 6/20 0.57
LMNA P02545 3/20 0.57
MET P08581 1/20 0.48
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
RECQL P46063 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MAPK1 P28482 2/20 0.44
GAA P10253 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
GRM5 P41594 1/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
CYP2D6 P10635 1/20 0.43
ALOX12 P18054 1/20 0.43
CYP1A2 P05177 1/20 0.43
KCNH2 Q12809 1/20 0.42
ENPP2 Q13822 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30481715 1.00 MAPT (0.57) MAPTALDH1A1LMNAMETMEN1
SCHEMBL30998112 0.87 MAPT (0.63) MAPTALDH1A1LMNAMETKMT2A
SCHEMBL4435451 0.87 MAPT (0.63) MAPTALDH1A1LMNAMETKMT2A
SCHEMBL1247295 0.86 MAPT (0.59) MAPTALDH1A1LMNAMETMEN1
SCHEMBL14309631 0.85 MAPT (0.51) MAPTALDH1A1LMNAMETMEN1
SCHEMBL28773828 0.85 MAPT (0.58) MAPTALDH1A1LMNAMETMEN1
SCHEMBL29608605 0.85 MAPT (0.58) MAPTALDH1A1LMNAMETMEN1
SCHEMBL30965630 0.84 MAPT (0.55) MAPTALDH1A1LMNAMETMEN1
SCHEMBL30965811 0.84 MAPT (0.55) MAPTALDH1A1LMNAMETMEN1
SCHEMBL521410 0.84 MAPT (0.55) MAPTALDH1A1LMNAMETMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691971-B2 Naphthyridinone compounds as JAK2 V617F inhibitors INCYTE CORPORATION (US) 2023-07-04 US disclosed
US-11691971-B2 Naphthyridinone compounds as JAK2 V617F inhibitors INCYTE CORPORATION (US) 2023-07-04 US disclosed
US-11691971-B2 Naphthyridinone compounds as JAK2 V617F inhibitors INCYTE CORPORATION (US) 2023-07-04 US disclosed
US-20210395251-A1 NAPHTHYRIDINONE COMPOUNDS AS JAK2 V617F INHIBITORS INCYTE CORPORATION 2021-12-23 US disclosed
US-20210395251-A1 NAPHTHYRIDINONE COMPOUNDS AS JAK2 V617F INHIBITORS INCYTE CORPORATION 2021-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691971-B2 Naphthyridinone compounds as JAK2 V617F inhibitors JAK2, JAK1, JAK3 MAPT 4706/4885ALDH1A1 2897/4885LMNA 2529/4885
US-20210395251-A1 NAPHTHYRIDINONE COMPOUNDS AS JAK2 V617F INHIBITORS JAK2, JAK1, JAK3 MAPT 4706/4885ALDH1A1 2897/4885LMNA 2529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.